Abstract: A method for treating a pro-tumor immune response in an individual having, or suspected of having, a pro-tumor immune response, by administering a therapeutically effective amount of an immunotherapeutic composition which binds to a determinant on B cells, resulting in B cell depletion including of B cells that may be involved in promotion of tumor progression. Also provided are immunotherapeutic compositions which can be used for treating a pro-tumor immune response.
Abstract: An isolated nucleotide sequence encoding human leukotriene C4 synthase or variants of human leukotriene C4 synthase polypeptide, is provided. One embodiment is an isolated DNA sequence (SEQ ID NO.:1) encoding a human leukotriene C4 synthase polypeptide, that has three hydrophobic transmembrane domains. Also described are recombinant cells and plasmids containing the foregoing isolated DNA, preferably linked to a promoter. Isolated leukotriene C4 synthase is provided, having at least three hydrophobic transmembrane domains (SEQ ID NO.:2). Portions of the foregoing isolated human leukotriene C4 synthase polypeptide are also described. Antibodies with selective binding specificity for the polypeptides of the invention also are provided as well as a sensitive method for assay of human leukotriene C4. Methods for producing leukotriene C4 synthase as well as methods for testing for modulators of leukotriene C4 synthase activity are also described.
Type:
Grant
Filed:
December 8, 1997
Date of Patent:
April 24, 2001
Assignee:
Brigham and Women's Hospital
Inventors:
Bing K. Lam, John F. Penrose, K. Frank Austen
Abstract: Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 17, 2001
Assignee:
Rhone-Poulenc Rorer International (Holdings), Inc.
Inventors:
Joseph Schlessinger, David Givol, Francoise Bellot, Richard Kris, George A. Ricca, Christopher Cheadle, Victoria J. South
Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.
Abstract: Disclosed is a method for treating tissue necrosis (loss) in an animal. Tissue necrosis is treated by providing the subject with an anti-adhesion cell agent capable of binding an ICAM-1 antigen, a CD18 antigen, an L-selectin agent, a CD44 antigen, a P-selectin antigen, a VCAM-1 antigen, an ICAM-2 antigen, or a fragment thereof. Also provided is a method for preventing thermal-related tissue loss or necrosis, particularly the thermal injury and progressive tissue necrosis which results from a burn injury. Thermal-related tissue injury surrounding a thermal injury site is inhibited or prevented by providing an animal with an anti-adhesion agent, such as an anti-CD18 antibody, an anti-ICAM-1 antibody, or a mixture or fragment thereof. A method for inhibiting/preventing scarring attendant healing of a thermal injury is also disclosed.
Type:
Grant
Filed:
April 2, 1997
Date of Patent:
March 20, 2001
Assignee:
Board of Regents of the University of Texas System
Abstract: The invention involves the therapeutic use of humanized antibodies, fragments, etc., which bind to the antigen A33. These antibody molecules are useful in the treatment of various neoplasias, including colon cancer. Various modes of administration, and doses are described.
Type:
Grant
Filed:
November 19, 1996
Date of Patent:
February 20, 2001
Assignees:
Ludwig Institute for Cancer Research, Sloan-Kettering Institute for Cancer Research
Inventors:
Sydney Welt, Gerd Ritter, Leonard Cohen, Clarence Williams, Jr., Elizabeth Carswell Richards, Mary John, Lloyd J. Old
Abstract: B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.
Abstract: This invention provides a monoclonal antibody which recognizes an epitope corresponding to amino acids 10 to 220, amino acids 221 to 297, or amino acids 469 to 662, counting from the N-terminus of a human Mx protein MxA, and specifically reacts with the human Mx protein by western blotting, immunoprecipitation or immunocyte staining, and a hybridoma which produces the antibody. The human Mx protein MxA monoclonal antibody of this invention can be used, for example, in the diagnosis of viral infection.
Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the B- or &ggr;subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed. including treating allograft rejection and graft-versus-host disease.
Type:
Grant
Filed:
November 20, 1998
Date of Patent:
January 23, 2001
Assignee:
Immunex Corporation
Inventors:
Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
Abstract: The peptide EPPT (Glu-Pro-Pro-Thr)(SEQ I YD NO:1) selectively binds a mucin expressed by epithelial tumors. It may be incorporated into larger molecules, such as, peptides consisting of the sequence EPPT and further amino acids to form a peptide of up to 30 amino acids, and may be radiolabelled or used to guide toxins, etc. to cells expressing the mucin.
Abstract: Monoclonal antibodies that recognize the &agr;v &bgr;3 integrin receptor complex, but do not significantly bind to &agr;IIb&bgr;IIIa, inhibit &agr;v&bgr;3 integrin-mediated diseases.
Type:
Grant
Filed:
April 9, 1998
Date of Patent:
January 9, 2001
Assignee:
G. D. Searle & Company
Inventors:
Christopher P. Carron, Debra M. Meyer, George A. Nickols
Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.
Type:
Grant
Filed:
June 12, 1998
Date of Patent:
January 9, 2001
Assignee:
Genentech, Inc.
Inventors:
Xanthe M. Lam, James Q. Oeswein, Boonsri Ongpipattanakul, Zahra Shahrokh, Sharon X. Wang, Robert P. Weissburg, Rita L. Wong